Exploration of sugar-based inhibitors of glycolysis to target brain tumors

Waldemar Priebe 1Marcin Cybulski 1,2Sławomir Szymański Izabela Skóra Stanisław Skóra Charles A. Conrad Timothy Madden 3

1. The University of Texas M D Anderson Cancer Center, Holcombe Boulevard 1515, Houston, TX 77030, United States
2. Instytut Farmaceutyczny (PRI), Rydygiera 8, Warszawa 01-793, Poland
3. Argonne National Laboratory (ANL), 9700 South Cass Avenue, Argonne, IL 60439, United States

Abstract

Glycolysis is the major energy producing pathway for fast growing, glycolytically dependent tumors, such as gliomas and ependymomas. Blocking glycolysis is, therefore, an important and clinically unexplored therapeutic strategy when used alone or as a combination therapy to enhance the effects of chemotherapy in energy-starved tumors.

In our studies, we have examined D-glucose antimetabolites 2-deoxy-D-glucose (2-DG), 2-deoxy-2-fluoro-D-glucose (2-FG) and 2-deoxy-2-fluoro-D-mannose (2-FM) and confirmed their ability to block glycolysis and discovered their ability to induce autophagic cell death.

Our more detail evaluation revealed that these compounds do not possess sufficient drug-like properties   (reasonable biostability, pharmacokinetic characteristics, or distribution to the target) to warrant further investigations into their clinical effectiveness. In an attempt to improve the pharmacokinetic profile of 2-DG, we have designed, synthesized, and tested a series of prodrugs that enhance biostability, biodistribution, and delivery of 2-DG to its CNS target.  We will present the synthesis and preliminary evaluation of compounds, leading to the selection of WP1122 as our lead compound for further drug development.

Legal notice
  • Legal notice:

    Copyrighted materials, (c) Pielaszek Research, all rights reserved.
    The above materials, including auxiliary resources, are subject to Publisher's copyright and the Author(s) intellectual rights. Without limiting Author(s) rights under respective Copyright Transfer Agreement, no part of the above documents may be reproduced, stored in or introduced into a retrieval or caching system, or transmitted in any form or by any means (electronic, mechanical, photocopying, recording or otherwise), or for any purpose, without the express written permission of Pielaszek Research, the Publisher. Express permission from the Author(s) is required to use the above materials for academic purposes, such as lectures or scientific presentations.
    In every case, proper references including Author(s) name(s) and URL of this webpage: http://science24.com/paper/22864 must be provided.

 

Related papers
  1. Determination of organic volatile impurities in Nepafenac by GC method
  2. Evaluation of potential genotoxic impurities in prasugrel intermediate by HPLC chromatography
  3. Simultaneous CE determination of counterion and possible impurity from synthetic route in pharmaceutical substance prasugrel hydrochloride.
  4. Efficient preparation of a key intermediate in the exemestane synthesis
  5. Determination of reaction progress in synthesis of EE-3 by NMR technique
  6. The evaluation of tolterodine tartrate synthesis based on patent EP 0 325 574 B1.
  7. HPLC as a method for analytical control of synthesis and determination of tolterodine (TD-S)
  8. Searching for lead molecules as potential new CNS agents in the serotonin 5-HT6 screening assay
  9. Targeting DNA: A Modular Approach Using Structure-Based Design and Combinatorial Libraries
  10. THE DISCOVERY AND DEVELOPMENT OF BLOOD-BRAIN BARRIER (BBB) PENETRATING ANTHRACYCLINES FOR THE TREATMENT OF BRAIN TUMORS
  11. New array detector for protein crystallography at the Argonne National Laboratory

Presentation: Invited oral at VII Multidyscyplinarna Konferencja Nauki o Leku, by Waldemar Priebe
See On-line Journal of VII Multidyscyplinarna Konferencja Nauki o Leku

Submitted: 2010-03-04 09:01
Revised:   2010-03-06 10:48
Google
 
Web science24.com
© 1998-2021 pielaszek research, all rights reserved Powered by the Conference Engine